These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 12706934)
1. Angiotensin-converting enzyme inhibition but not angiotensin II type 1 receptor antagonism augments coronary release of tissue plasminogen activator in hypertensive patients. Matsumoto T; Minai K; Horie H; Ohira N; Takashima H; Tarutani Y; Yasuda Y; Ozawa T; Matsuo S; Kinoshita M; Horie M J Am Coll Cardiol; 2003 Apr; 41(8):1373-9. PubMed ID: 12706934 [TBL] [Abstract][Full Text] [Related]
2. Bradykinin stimulates the release of tissue plasminogen activator in human coronary circulation: effects of angiotensin-converting enzyme inhibitors. Minai K; Matsumoto T; Horie H; Ohira N; Takashima H; Yokohama H; Kinoshita M J Am Coll Cardiol; 2001 May; 37(6):1565-70. PubMed ID: 11345366 [TBL] [Abstract][Full Text] [Related]
3. Effects of angiotensin converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension. Erdem Y; Usalan C; Haznedaroğlu IC; Altun B; Arici M; Yasavul U; Turgan C; Cağlar S Am J Hypertens; 1999 Nov; 12(11 Pt 1):1071-6. PubMed ID: 10604482 [TBL] [Abstract][Full Text] [Related]
4. Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans. Brown NJ; Agirbasli M; Vaughan DE Hypertension; 1999 Aug; 34(2):285-90. PubMed ID: 10454455 [TBL] [Abstract][Full Text] [Related]
5. Renin-angiotensin system is involved in the mechanism of increased serum asymmetric dimethylarginine in essential hypertension. Ito A; Egashira K; Narishige T; Muramatsu K; Takeshita A Jpn Circ J; 2001 Sep; 65(9):775-8. PubMed ID: 11548874 [TBL] [Abstract][Full Text] [Related]
6. Losartan and perindopril effects on plasma plasminogen activator inhibitor-1 and fibrinogen in hypertensive type 2 diabetic patients. Fogari R; Mugellini A; Zoppi A; Corradi L; Preti P; Lazzari P; Derosa G Am J Hypertens; 2002 Apr; 15(4 Pt 1):316-20. PubMed ID: 11991216 [TBL] [Abstract][Full Text] [Related]
7. Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure. Goodfield NE; Newby DE; Ludlam CA; Flapan AD Circulation; 1999 Jun; 99(23):2983-5. PubMed ID: 10368114 [TBL] [Abstract][Full Text] [Related]
8. Potentiation of bradykinin-induced tissue plasminogen activator release by angiotensin-converting enzyme inhibition. Labinjoh C; Newby DE; Pellegrini MP; Johnston NR; Boon NA; Webb DJ J Am Coll Cardiol; 2001 Nov; 38(5):1402-8. PubMed ID: 11691515 [TBL] [Abstract][Full Text] [Related]
9. Effects of a long-term pharmacological interruption of the renin-angiotensin system on the fibrinolytic system in essential hypertension. Sakata K; Pawlak R; Urano T; Takada A Pathophysiol Haemost Thromb; 2002; 32(2):67-75. PubMed ID: 12214151 [TBL] [Abstract][Full Text] [Related]
10. B1 kinin receptor does not contribute to vascular tone or tissue plasminogen activator release in the peripheral circulation of patients with heart failure. Cruden NL; Tse GH; Fox KA; Ludlam CA; Megson I; Newby DE Arterioscler Thromb Vasc Biol; 2005 Apr; 25(4):772-7. PubMed ID: 15681300 [TBL] [Abstract][Full Text] [Related]
11. Lack of involvement of bradykinin in the vascular sympathoinhibitory effects of angiotensin converting enzyme inhibitors in spontaneously hypertensive rats. Chauvin B; Richer C; Giudicelli JF Br J Pharmacol; 1995 Oct; 116(4):2229-36. PubMed ID: 8564253 [TBL] [Abstract][Full Text] [Related]
12. Brachial artery flow-mediated vasodilation is correlated with coronary vasomotor and fibrinolytic responses induced by bradykinin. Tarutani Y; Matsumoto T; Takashima H; Yamane T; Horie M Hypertens Res; 2005 Jan; 28(1):59-66. PubMed ID: 15969256 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of the Renin-Angiotensin System Post Myocardial Infarction Prevents Inflammation-Associated Acute Cardiac Rupture. Gao XM; Tsai A; Al-Sharea A; Su Y; Moore S; Han LP; Kiriazis H; Dart AM; Murphy AJ; Du XJ Cardiovasc Drugs Ther; 2017 Apr; 31(2):145-156. PubMed ID: 28204966 [TBL] [Abstract][Full Text] [Related]
14. Angiotensin-converting enzyme inhibition increases human vascular tissue-type plasminogen activator release through endogenous bradykinin. Pretorius M; Rosenbaum D; Vaughan DE; Brown NJ Circulation; 2003 Feb; 107(4):579-85. PubMed ID: 12566370 [TBL] [Abstract][Full Text] [Related]
16. Persistent effects on blood pressure and renal function of perindopril alone or combined with losartan in Lyon hypertensive rats. Naelten G; Liu KL; Chapuis B; Lo M Am J Hypertens; 2005 May; 18(5 Pt 1):699-706. PubMed ID: 15882554 [TBL] [Abstract][Full Text] [Related]
17. ACE inhibition versus angiotensin type 1 receptor antagonism: differential effects on PAI-1 over time. Brown NJ; Kumar S; Painter CA; Vaughan DE Hypertension; 2002 Dec; 40(6):859-65. PubMed ID: 12468570 [TBL] [Abstract][Full Text] [Related]
18. ACE inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients. Fogari R; Zoppi A; Lazzari P; Preti P; Mugellini A; Corradi L; Lusardi P J Cardiovasc Pharmacol; 1998 Oct; 32(4):616-20. PubMed ID: 9781930 [TBL] [Abstract][Full Text] [Related]
19. Angiotensin-converting enzyme inhibition augments coronary release of tissue plasminogen activator in women but not in men. Matsumoto T; Takashima H; Nakae I; Yamane T; Hayashi H; Horie M; Hypertension; 2010 Sep; 56(3):364-8. PubMed ID: 20606106 [TBL] [Abstract][Full Text] [Related]
20. Pharmacology of ACE inhibitors versus AT1 blockers. Vaughan D Can J Cardiol; 2000 Aug; 16 Suppl E():36E-40E. PubMed ID: 10906625 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]